Cellectar Biosciences Ownership
| CLRB Stock | USD 1.57 0.01 0.63% |
Shares in Circulation | First Issued 2005-03-31 | Previous Quarter 35.8 M | Current Value 39.8 M | Avarage Shares Outstanding 2.6 M | Quarterly Volatility 6.9 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Cellectar |
Cellectar Stock Ownership Analysis
About 35.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.41. Cellectar Biosciences last dividend was issued on the 17th of July 2018. The entity had 1:10 split on the 22nd of July 2022. Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. Cellectar Biosc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. For more info on Cellectar Biosciences please contact James Caruso at 608 441 8120 or go to https://www.cellectar.com.Besides selling stocks to institutional investors, Cellectar Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cellectar Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cellectar Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cellectar Biosciences Quarterly Liabilities And Stockholders Equity |
|
Roughly 3.0% of Cellectar Biosciences are currently held by insiders. Unlike Cellectar Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cellectar Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cellectar Biosciences' insider trades
Cellectar Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cellectar Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cellectar Biosciences backward and forwards among themselves. Cellectar Biosciences' institutional investor refers to the entity that pools money to purchase Cellectar Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2024-06-30 | 63.1 K | Northern Trust Corp | 2024-09-30 | 61.1 K | Xtx Topco Ltd | 2024-09-30 | 53 K | Jpmorgan Chase & Co | 2024-06-30 | 51.1 K | Susquehanna International Group, Llp | 2024-06-30 | 45.8 K | Millennium Management Llc | 2024-06-30 | 42.6 K | Jane Street Group Llc | 2024-06-30 | 41.9 K | Goldman Sachs Group Inc | 2024-06-30 | 35 K | Tower Research Capital Llc | 2024-06-30 | 31.8 K | Rosalind Advisors, Inc. | 2024-09-30 | 3.7 M | Aigh Capital Management, Llc | 2024-09-30 | 3.2 M |
Cellectar Biosciences Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cellectar Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cellectar Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cellectar Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jarrod Longcor over two months ago Acquisition by Jarrod Longcor of 450000 shares of Cellectar Biosciences at 1.74 subject to Rule 16b-3 | ||
Chanan-khan Asher over three months ago Acquisition by Chanan-khan Asher of 7800 shares of Cellectar Biosciences subject to Rule 16b-3 | ||
Chanan-khan Asher over three months ago Acquisition by Chanan-khan Asher of 60000 shares of Cellectar Biosciences at 2.58 subject to Rule 16b-3 | ||
Darrell Lea over six months ago Acquisition by Darrell Lea of 100000 shares of Cellectar Biosciences at 1.68 subject to Rule 16b-3 | ||
James Caruso over six months ago Acquisition by James Caruso of 40596 shares of Cellectar Biosciences subject to Rule 16b-3 | ||
John Neis over six months ago Acquisition by John Neis of 25000 shares of Cellectar Biosciences subject to Rule 16b-3 | ||
Stefan Loren over a year ago Acquisition by Stefan Loren of 25000 shares of Cellectar Biosciences subject to Rule 16b-3 | ||
Shustov Andrei over a year ago Cellectar Biosciences exotic insider transaction detected |
Cellectar Biosciences Outstanding Bonds
Cellectar Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cellectar Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cellectar bonds can be classified according to their maturity, which is the date when Cellectar Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| CELULOSA ARAUCO Y Corp BondUS151191BD46 | View | |
| CELARA 3875 02 NOV 27 Corp BondUS151191BB89 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| US15118JAA34 Corp BondUS15118JAA34 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Cellectar Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cellectar Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cellectar Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cellectar Biosciences Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cellectar Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Cellectar Stock refer to our How to Trade Cellectar Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cellectar Biosciences. If investors know Cellectar will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cellectar Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.41) | Return On Assets (1.66) | Return On Equity (7.97) |
The market value of Cellectar Biosciences is measured differently than its book value, which is the value of Cellectar that is recorded on the company's balance sheet. Investors also form their own opinion of Cellectar Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cellectar Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cellectar Biosciences' market value can be influenced by many factors that don't directly affect Cellectar Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cellectar Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cellectar Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cellectar Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.